Cogent Biosciences, Inc.
NASDAQCogent Biosciences enters September with an uncomfortable split: short sellers have been quietly adding positions for weeks while the analyst community sits firmly in the bull camp, leaving the stock caught between accumulating bearish pressure and a consensus price target implying roughly 60% upside from current levels. The short-side story has been steadily building. At 12.6% of…
Snapshot as of 23 Sept 2026
Cogent Biosciences enters September with an uncomfortable split: short sellers have been quietly adding positions for weeks while the analyst community sits firmly in the bull camp, leaving the stock caught between…
Cogent Biosciences printed its Q2 results on August 13 into a stock already down nearly 10% on the week — and the data since has shifted meaningfully from the bullish setup described in notes filed earlier this…
Cogent Biosciences heads into its August 13 print with the most call-skewed options market in a year — but a 10% short base and a November FDA decision that dwarfs anything the quarterly numbers can deliver. The…
Cogent Biosciences heads into its August 13 earnings report with options traders at their most bullish in a year and a meaningful short position that has started to retreat — a setup that makes the print feel secondary…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for COGT — free to start on ORTEX.
Sign up for free →Open COGT on ORTEX